A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

Summary

TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and determine the recommended dose and regimen(s) to initiate Phase 2.

Timeline

Start

2015-09

Primary completion

2017-04-29

Completion

2019-05-20

Drugs

Indications